Evidence map›Paper›PMID 40771806›Full record

ArticleFrontiers in immunology2025

Pierre Gaudeaux, Juliette Paillet, Monah Abou Alezz, Ranjita Devi Moirangthem, Sara Cascione, Marta Martin Corredera, Anne-Catherine Dolens, Katrien De Mulder, Imke Velghe, Bart Vandekerckhove and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Pierre Gaudeaux *Laboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Juliette Paillet *Laboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Monah Abou AlezzSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ranjita Devi MoirangthemLaboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Sara CascioneSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marta Martin CorrederaLaboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Anne-Catherine DolensCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Katrien De MulderCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Imke VelgheCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Bart VandekerckhoveCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Marieke LavaertCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Noémie RobilGenoSplice, Paris, France.
Aurélien CorneauCentre de recherche Saint-Antoine, CISA, Sorbonne Université, Paris, France.
Hanem SadekSmart Immune, Paris, France.
Pauline RaultSmart Immune, Paris, France.
Akshay JoshiLaboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Pierre de la GrangeGenoSplice, Paris, France.
Frank J T StaalDepartment of Pediatrics, Pediatric Stem Cell Transplantation Program, Willem-Alexander Children's Hospital, Leiden, Netherlands.
Tom TaghonCancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Olivier NegreSmart Immune, Paris, France.
Andrea Ditadi *San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Isabelle André *Laboratory of Human Lymphohematopoieisis, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France.
Tayebeh-Shabi Soheili *Smart Immune, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We previously established a feeder-free cell therapy platform for the Method: To further explore the full therapeutic potential of this cell product, we performed a comprehensive molecular and phenotypic characterization using single cell RNA sequencing and mass cytometry analysis. Results: Our analysis revealed the presence of distinct cell subsets within the cellular product characterized mainly by commitment to lymphoid lineages. Using integrated transcriptomic analyses to compare these Conclusion: These findings underscore the versatility of DLL4-based lymphoid progenitors in generating either T cells or ILCs in response to environmental cues. This research paves the way for innovative cell therapy approaches to treat immune deficiencies and cancer- and age-related immune dysfunctions.

Indexed as

Immunity, InnateLymphocytesLymphoid Progenitor CellsT-LymphocytesCell DifferentiationCell LineageCells, CulturedHumansKiller Cells, NaturalSingle-Cell Analysisex vivo differentiationhematopoietic stem celllymphoid cell developmentscRNAseqT cell progenitors

Identifiers

PMID40771806
PMCPMC12325321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.